Cognition Therapeutics Awarded $6.6M to Support 2 Elayta Trials for Alzheimer’s

Cognition Therapeutics Awarded $6.6M to Support 2 Elayta Trials for Alzheimer’s
Cognition Therapeutics has received two multi-year grants from the National Institute on Aging (NIA) totaling $6.6 million to fund two clinical studies of Elayta (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. Elayta is a brain-penetrating small molecule with a unique disease-modifying mechanism of action. The compound protects synapses — tiny connections between nerve cells that allows them to communicate — by displacing beta-amyloid oligomers from their binding sites on nerve cells. Beta-amyloid is the protein that accumulates in the brains of Alzheimer’s patients and causes nerve cells to die. In preclinical models of Alzheimer’s, the oral investigational compound restored synapse numbers and improved memory function. In a Phase 1b/2a clinical study (NCT02907567), Elayta significantly reduced concentrations of synapse damaging proteins in the cerebrospinal fluid of Alzheimer’s patients, improving the activity of patients' brain cells. The NIA grant will help fund the Phase 1 target-engagement SNAP study (NCT03522129) and the Phase 1/2 synaptic-protection SPARC trial (NCT03493282). Both trials are currently recruiting and are expected to begin dosing patients this year. The SNAP trial is a multicenter, randomized, double-blind, placebo-controlled, study in 18 adults with mild-to-moderate Alzheimer’s who will receive a single dose of either Elayta or placebo. At the end of the study, patients' cerebrospinal fluid and blood plasma beta-amyloid and Elayta levels will be monitored to determine if treatment with Elayta induces decreased beta-amyloid aggregates in brain nerve cells. The study will be conducted at the University of Pennsylvania. The SPARC study is a synaptic protecti
Subscribe or to access all post and page content.